Ultragenyx Pharmaceutical RARE Non Cash Interest Expense On Liability Related To Sale Of Future Royalties
Non Cash Interest Expense On Liability Related To Sale Of Future Royalties at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept rare:NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties.
The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ultragenyx Pharmaceutical's non cash interest expense on liability related to sale of future royalties.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ultragenyx Pharmaceutical's non cash interest expense on liability related to sale of future royalties?
- Ultragenyx Pharmaceutical (RARE) reported non cash interest expense on liability related to sale of future royalties of $21M in Q1 2026.
- How has Ultragenyx Pharmaceutical's non cash interest expense on liability related to sale of future royalties changed year-over-year?
- Ultragenyx Pharmaceutical's non cash interest expense on liability related to sale of future royalties increased by 50.0% year-over-year, from $14M to $21M.
- What is the long-term trend for Ultragenyx Pharmaceutical's non cash interest expense on liability related to sale of future royalties?
- Over 4 years (2021 to 2025), Ultragenyx Pharmaceutical's non cash interest expense on liability related to sale of future royalties has grown at a 20.3% compound annual growth rate (CAGR), from $29.42M to $61.66M.
- What does non cash interest expense on liability related to sale of future royalties mean?
- This metric captures the non-cash interest charges associated with financial obligations linked to the monetization of future royalty streams. It reflects the financing cost of capital raised by selling rights to future revenue, rather than traditional debt instruments. Investors track this to understand the impact of alternative financing structures on the company's long-term capital obligations and non-operating expenses.